Human gastrin- releasing peptide receptor expression in women with uterine cervix cancer

20237 citationsJournal Articlegold Open Access

Authors

Charles A. Kunos · University of Kentucky

Denise Fabian · University of Kentucky

Dana Napier · University of Kentucky

Mark S. Stonecypher · Molecular Pathology Laboratory Network (United States)

Ravyn M. Duncan · Molecular Pathology Laboratory Network (United States)

Jason Hurt · Orano (United States)

Abstract

The frequency of overexpression in this study suggests that <sup>212</sup>Pb-DOTAM-GRPR1 radiopharmaceutical treatment may be useful in the management of persistent, recurrent, or metastatic uterine cervix cancer patients. A phase I clinical trial involving patients with metastatic uterine cervix cancer is currently underway (NCT05283330).

Topics & Keywords

Endometrial and Cervical Cancer Treatments Lung Cancer Research Studies Neuroendocrine Tumor Research Advances

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Oncology

Volume 13, pp. 1126426-1126426

DOI: 10.3389/fonc.2023.1126426

Field-Weighted Citation Impact: 2.10